

S3 Text. Profile likelihood and sensitivity of model fit to assumed parameters

In the profile likelihood plots, the red dot indicates the maximum likelihood estimate, the black dots are the best binned output from the global optimization process, the black line shows the continuous approximation to the profile likelihood, and the blue dashed line indicates the threshold value for the confidence interval (the maximum log-likelihood value plus half the 95% percentile for the χ^2 distribution for k degrees of freedom; S1 Text). In the sensitivity analysis plots, the red dot indicates the maximum likelihood estimate for the baseline value (Table 1), the black line shows the log-likelihood for the alternative parameter value, and the blue dashed line (the maximum log-likelihood value plus half the 95% percentile for the χ^2 distribution for one degree of freedom) is an indicator of when the quality of the fit becomes significantly worse.

Contents






1 Likelihood profiles: Control macaques	3
1.1 Baseline effector cell source model	3
1.2 Saturated effector cell source model	7
1.3 Antigen presenting cell effector cell source model	14
2 Sensitivity analysis: Control macaques	18
2.1 Baseline effector cell source model	18
2.2 Saturated effector cell source model	22
2.3 Antigen presenting cell effector cell source model	26
3 Likelihood profiles: Increased viral clearance	30
3.1 Baseline effector cell source model	30
3.2 Saturated effector cell source model	35
3.3 Antigen presenting cell effector cell source model	40
4 Sensitivity analysis: Increased viral clearance	45
4.1 Baseline effector cell source model	45
4.2 Saturated effector cell source model	50
4.3 Antigen presenting cell effector cell source model	55
5 Likelihood profiles: Viral neutralization	60
5.1 Baseline effector cell source model	60
5.2 Saturated effector cell source model	65
5.3 Antigen presenting cell effector cell source model	70

6	Sensitivity analysis: Viral neutralization	75
6.1	Baseline effector cell source model	75
6.2	Saturated effector cell source model	80
6.3	Antigen presenting cell effector cell source model	85
7	Likelihood profiles: Protection	90
7.1	Baseline effector cell source model	90
7.2	Saturated effector cell source model	95
7.3	Antigen presenting cell effector cell source model	100
8	Sensitivity analysis: Protection	105
8.1	Baseline effector cell source model	105
8.2	Saturated effector cell source model	110
8.3	Antigen presenting cell effector cell source model	115
9	Likelihood profiles: Increased antigen presentation	120
9.1	Baseline effector cell source model	120
9.2	Saturated effector cell source model	124
9.3	Antigen presenting cell effector cell source model	129
10	Sensitivity analysis: Increased antigen presentation	134
10.1	Baseline effector cell source model	134
10.2	Saturated effector cell source model	139
10.3	Antigen presenting cell effector cell source model	144
11	Likelihood profiles: Increased antigen presentation with increased viral clearance	149
11.1	Baseline effector cell source model	149
11.2	Saturated effector cell source model	154
11.3	Antigen presenting cell effector cell source model	159
12	Sensitivity analysis: Increased antigen presentation with increased viral clearance	164
12.1	Baseline effector cell source model	164
12.2	Saturated effector cell source model	169
12.3	Antigen presenting cell effector cell source model	174






1 Likelihood profiles: Control macaques

1.1 Baseline effector cell source model






RBe14: Control (BL)








Rlt11: Control (BL)








RKs13: Control (BL)








RSy13: Control (BL)








RYy13: Control (BL)



RLo14: Control (BL)









RUs14: Control (BL)









1.2 Saturated effector cell source model







RBe14: Control (SS)









Rlt11: Control (SS)









RKs13: Control (SS)









RSy13: Control (SS)









RYY13: Control (SS)



RLo14: Control (SS)








RUs14: Control (SS)








1.3 Antigen presenting cell effector cell source model






RBe14: Control (APCS)








Rlt11: Control (APCS)








RKs13: Control (APCS)








RSy13: Control (APCS)








RYy13: Control (APCS)



RLo14: Control (APCS)




RUs14: Control (APCS)




2 Sensitivity analysis: Control macaques

2.1 Baseline effector cell source model


RBe14: Control (BL)




Rt11: Control (BL)




RKs13: Control (BL)




RSy13: Control (BL)




RYy13: Control (BL)



RLo14: Control (BL)




RU14: Control (BL)




2.2 Saturated effector cell source model


RBe14: Control (SS)




RIt11: Control (SS)




RKs13: Control (SS)




RSy13: Control (SS)




Ry13: Control (SS)



RLo14: Control (SS)




RUs14: Control (SS)




2.3 Antigen presenting cell effector cell source model


RBe14: Control (APS)




Rlt11: Control (APS)




RKs13: Control (APS)




RSy13: Control (APS)




RyY13: Control (APS)



RL014: Control (APS)








RU14: Control (APS)









3 Likelihood profiles: Increased viral clearance

3.1 Baseline effector cell source model

















ROv14: Increased viral clearance (BL)




3.2 Saturated effector cell source model


ROq14: Increased viral clearance (SS)




RDa15: Increased viral clearance (SS)




RFa15: Increased viral clearance (SS)




RLn12: Increased viral clearance (SS)




RId14: Increased viral clearance (SS)




ROo13:Increased viral clearance (SS)




RSd14:Increased viral clearance (SS)





ROv14: Increased viral clearance (SS)





3.3 Antigen presenting cell effector cell source model









RLn12:Increased viral clearance (APCS)





RId14:Increased viral clearance (APCS)











ROo13: Increased viral clearance (APCS)



RSd14: Increased viral clearance (APCS)




ROv14: Increased viral clearance (APCS)




4 Sensitivity analysis: Increased viral clearance

4.1 Baseline effector cell source model


ROq14: Increased viral clearance (BL)




RDa15: Increased viral clearance (BL)




RFa15: Increased viral clearance (BL)




RLn12: Increased viral clearance (BL)




Rld14: Increased viral clearance (BL)




ROo13: Increased viral clearance (BL)



RSd14: Increased viral clearance (BL)




ROV14: Increased viral clearance (BL)




4.2 Saturated effector cell source model


ROq14: Increased viral clearance (SS)




RDa15: Increased viral clearance (SS)




RFa15: Increased viral clearance (SS)




RLn12: Increased viral clearance (SS)




Rld14: Increased viral clearance (SS)




ROo13:Increased viral clearance (SS)



RSd14:Increased viral clearance (SS)




ROv14: Increased viral clearance (SS)




4.3 Antigen presenting cell effector cell source model


ROq14: Increased viral clearance (APCS)




RDa15:Increased viral clearance (APCS)




RFa15:Increased viral clearance (APCS)




RLn12: Increased viral clearance (APCS)




Rld14: Increased viral clearance (APCS)




ROo13:Increased viral clearance (APCS)



RSd14:Increased viral clearance (APCS)








ROv14: Increased viral clearance (APCS)











5 Likelihood profiles: Viral neutralization

5.1 Baseline effector cell source model

















ROV14:Viral neutralization (BL)




5.2 Saturated effector cell source model


ROq14:Viral neutralization (SS)




RDa15:Viral neutralization (SS)




RFa15:Viral neutralization (SS)




RLn12:Viral neutralization (SS)




Rld14:Viral neutralization (SS)




ROo13:Viral neutralization (SS)




RSd14:Viral neutralization (SS)




ROv14:Viral neutralization (SS)





5.3 Antigen presenting cell effector cell source model











RLn12:Viral neutralization (APCS)





RId14:Viral neutralization (APCS)






ROv14:Viral neutralization (APCS)




6 Sensitivity analysis: Viral neutralization

6.1 Baseline effector cell source model


ROq14:Viral neutralization (BL)




RDa15:Viral neutralization (BL)




RFa15:Viral neutralization (BL)




RLn12:Viral neutralization (BL)




Rld14:Viral neutralization (BL)




ROo13:Viral neutralization (BL)



RSd14:Viral neutralization (BL)




ROv14:Viral neutralization (BL)




6.2 Saturated effector cell source model


ROq14:Viral neutralization (SS)




RDa15:Viral neutralization (SS)




RFa15:Viral neutralization (SS)




Rln12:Viral neutralization (SS)




Rld14:Viral neutralization (SS)




ROo13:Viral neutralization (SS)



RSd14:Viral neutralization (SS)




ROv14:Viral neutralization (SS)




6.3 Antigen presenting cell effector cell source model


ROq14:Viral neutralization (APCS)




RDa15:Viral neutralization (APCS)




RFa15:Viral neutralization (APCS)




RLn12:Viral neutralization (APCS)




Rld14:Viral neutralization (APCS)




ROo13:Viral neutralization (APCS)



RSd14:Viral neutralization (APCS)








ROV14:Viral neutralization (APCS)










7 Likelihood profiles: Protection

7.1 Baseline effector cell source model
















RLn12:Protection (BL)





RId14:Protection (BL)






ROv14:Protection (BL)




7.2 Saturated effector cell source model


ROq14:Protection (SS)




RDa15:Protection (SS)




RFa15:Protection (SS)




RLn12:Protection (SS)




Rld14:Protection (SS)




ROo13:Protection (SS)




RSd14:Protection (SS)











ROv14:Protection (SS)





7.3 Antigen presenting cell effector cell source model











ROo13:Protection (APCS)



RSd14:Protection (APCS)




ROv14:Protection (APCS)




8 Sensitivity analysis: Protection

8.1 Baseline effector cell source model


ROq14:Protection (BL)




RDa15:Protection (BL)




RFa15:Protection (BL)




RLn12:Protection (BL)




Rld14:Protection (BL)




ROo13:Protection (BL)



RSd14:Protection (BL)




ROV14:Protection (BL)




8.2 Saturated effector cell source model


ROq14:Protection (SS)




RDa15:Protection (SS)




RFa15:Protection (SS)




RLn12:Protection (SS)




Rld14:Protection (SS)




ROo13:Protection (SS)



RSd14:Protection (SS)




ROv14:Protection (SS)




8.3 Antigen presenting cell effector cell source model


ROq14:Protection (APCS)




RDa15:Protection (APCS)




RFa15:Protection (APCS)




RLn12:Protection (APCS)




Rl14:Protection (APCS)




ROo13:Protection (APCS)



RSd14:Protection (APCS)




ROv14:Protection (APCS)





9 Likelihood profiles: Increased antigen presentation



9.1 Baseline effector cell source model





RFa15:Increased antigen presentation (BL)





RLn12:Increased antigen presentation (BL)





RId14: Increased antigen presentation (BL)




ROo13: Increased antigen presentation (BL)








9.2 Saturated effector cell source model

ROq14: Increased antigen presentation (SS)







RLn12:Increased antigen presentation (SS)




Rld14:Increased antigen presentation (SS)




ROo13: Increased antigen presentation (SS)




RSd14: Increased antigen presentation (SS)










ROv14: Increased antigen presentation (SS)










9.3 Antigen presenting cell effector cell source model










RDa15:Increased antigen presentation (APCS)










RFa15:Increased antigen presentation (APCS)





RLn12: Increased antigen presentation (APCS)





Rld14: Increased antigen presentation (APCS)










ROo13:Increased antigen presentation (APCS)



RSd14:Increased antigen presentation (APCS)




ROv14: Increased antigen presentation (APCS)




10 Sensitivity analysis: Increased antigen presentation

10.1 Baseline effector cell source model


ROq14:Increased antigen presentation (BL)




RDa15: Increased antigen presentation (BL)




RFa15: Increased antigen presentation (BL)




RLn12: Increased antigen presentation (BL)




Rld14: Increased antigen presentation (BL)




ROo13: Increased antigen presentation (BL)



RSd14: Increased antigen presentation (BL)




ROv14: Increased antigen presentation (BL)




10.2 Saturated effector cell source model


ROq14: Increased antigen presentation (SS)




RDa15: Increased antigen presentation (SS)




RFa15: Increased antigen presentation (SS)




RLn12: Increased antigen presentation (SS)




Rld14: Increased antigen presentation (SS)




ROo13: Increased antigen presentation (SS)



RSd14: Increased antigen presentation (SS)




ROv14: Increased antigen presentation (SS)




10.3 Antigen presenting cell effector cell source model


ROq14: Increased antigen presentation (APCS)




RDa15:Increased antigen presentation (APCS)




RFa15:Increased antigen presentation (APCS)




RLn12:Increased antigen presentation (APCS)




Rld14:Increased antigen presentation (APCS)




ROo13: Increased antigen presentation (APCS)



RSd14: Increased antigen presentation (APCS)




ROv14: Increased antigen presentation (APCS)





11 Likelihood profiles: Increased antigen presentation with increased viral clearance



11.1 Baseline effector cell source model











RDa15: Increased antigen presentation with clearance (BL)





RFa15: Increased antigen presentation with clearance (BL)








ROV14: Increased antigen presentation with clearance (BL)




11.2 Saturated effector cell source model


ROq14: Increased antigen presentation with clearance (SS)




RDa15: Increased antigen presentation with clearance (SS)




RFa15: Increased antigen presentation with clearance (SS)




RLn12: Increased antigen presentation with clearance (SS)




Rld14: Increased antigen presentation with clearance (SS)




ROo13: Increased antigen presentation with clearance (SS)




RSd14: Increased antigen presentation with clearance (SS)







ROv14: Increased antigen presentation with clearance (SS)





11.3 Antigen presenting cell effector cell source model











RLn12: Increased antigen presentation with clearance (APCS)





Rld14: Increased antigen presentation with clearance (APCS)






ROV14: Increased antigen presentation with clearance (APCS)




12 Sensitivity analysis: Increased antigen presentation with increased viral clearance

12.1 Baseline effector cell source model


ROq14: Increased antigen presentation with clearance (BL)




RDa15: Increased antigen presentation with clearance (BL)




RFa15: Increased antigen presentation with clearance (BL)




RLn12: Increased antigen presentation with clearance (BL)




Rld14: Increased antigen presentation with clearance (BL)




ROo13: Increased antigen presentation with clearance (BL)



RSd14: Increased antigen presentation with clearance (BL)




ROV14: Increased antigen presentation with clearance (BL)




12.2 Saturated effector cell source model


ROq14: Increased antigen presentation with clearance (SS)




RDa15: Increased antigen presentation with clearance (SS)




RFa15: Increased antigen presentation with clearance (SS)




RLn12: Increased antigen presentation with clearance (SS)




Rld14: Increased antigen presentation with clearance (SS)




ROo13: Increased antigen presentation with clearance (SS)



RSd14: Increased antigen presentation with clearance (SS)




ROV14: Increased antigen presentation with clearance (SS)




12.3 Antigen presenting cell effector cell source model


ROq14: Increased antigen presentation with clearance (APCS)




RDa15: Increased antigen presentation with clearance (APCS)




RFa15: Increased antigen presentation with clearance (APCS)




RLn12: Increased antigen presentation with clearance (APCS)




Rl14: Increased antigen presentation with clearance (APCS)



ROo13: Increased antigen presentation with clearance (APCS)



RSd14: Increased antigen presentation with clearance (APCS)



ROv14: Increased antigen presentation with clearance (APCS)

